

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

\_\_\_\_\_  
Type or print name of person signing certification

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant: FERRITTO CRESPO, Rafael

Serial No.: 10/517581

Application Date: June 11, 2003

US Nat'l Entry Date (if applicable): December 8, 2004

For: AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR  
MODULATORS

Docket No.: X-14844

Group Art Unit: 1624

Examiner: S. Moore

Conf No.: 1754

**RESPONSE TO THE RESTRICTION REQUIREMENT**  
**SUBMITTED UNDER 35 USC §121**

Mail Stop Amendment  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450  
Facsimile No.: 571-273-8300

**Introductory Comments**

Sir:

In response to the Restriction Requirement dated June 28, 2006, for the above identified application, entry of the following is respectfully requested.

This paper is filed in response to the restriction requirement mailed June 28, 2006. Claims 1- 9, 11, 12, 14-18, 20-23, 25-28, 30, 32-34, 36 and 40-45 are currently pending

in the application and are subject to the following restriction pursuant to 35 U.S.C. 121 and 372:

Group I, claims 1-3, 11, 15-18, 20, 21, 23, 25, 30, 32-34, 36 and 43 wherein NR1R2 form a piperazine ring.

Group II, claims 1-3, 11, 15-18, 20-22, 30, 32-34, 36 and 43 wherein NR1R2 form a piperidine ring.

Group III, claims 1-3, 11, 15-18, 20, 21, 30, 32-34, 36 and 43 wherein NR1R2 form a dihydroisoquinoline ring.

Group IV, claims 1-3, 15-18, 20, 21, 30, 32-34, 36 and 43 wherein NR1R2 form another heterocyclic ring not set forth by Groups I-III.

Group V, claims 1-5, 7, 9, 12, 15-18, 20, 21, 30, 32-34, 36, 41, and 43 wherein R2 is thiadiazole.

Group VI, 1-5, 7, 9, 15-18, 20, 21, 30, 32-34, 36, 41, and 43 wherein R2 is thiazole.

Group VII, claims 1-5, 7, 9, 12, 15-18, 20, 21, 30, 32-34, 36, 41, and 43, wherein R2 is benzthiazole.

Group VIII, claims 1-5, 7, 9, 12, 15-18, 20, 21, 26, 27, 30, 32-34, 36, 41, and 43, wherein R2 is another heterocyclic ring not found in Groups V-VII.

Group IX, claims 1-6, 9, 14-18, 20, 21, 26-28, 30, 32-34, 36 and 40-45, drawn to compounds wherein R2 is a non-heteroamide moiety, compositions, and methods of treatment.

The Examiner requested Applicants to elect a single invention to which the claims must be restricted. Applicants hereby elect Group IX claims 1-6, 9, 14-18, 20, 21, 26-28, 30, 32-34, 36 and 40-45, drawn to compounds wherein R2 is a non-heteroamide moiety, compositions, and methods of treatment, without traverse. Applicants elect the compound of Examples 42, 99, and 106B, solely as an election of species to aid the Examiner in the searching and examination process.

Applicants provide herein a preliminary amendment to Claim 1 with current listing of the claims. The amendments to the Claims begin on page 4. A complete listing

of the current claims is included and shall replace all previous versions of the claims.

Entry of the amendments to the Claims is respectfully requested.